Prospective Clinical Study of a Combined Regime of Tripterygium Wilfordii Plus Benazepril and Emodin in Treatment of IgA Nephropathy

徐明中,胡伟新,刘志红,唐政,陈惠萍,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298x.2004.01.004

2004-01-01

Abstract:Objective: The prognosis of IgA nephropathy patients with proteinuria and/or alimierated renal function fares much worse than those without. And no consensusized regime is available clinically for this groups of patients besides symptomatic approaches with respect of proteinuria and hypertension. In this paper, we reported a combined regime with tripterygium wilfordii plus benazepril and emodin for IgA nephropathy (IgAN), and prospectively observe the effects in both clinic and pathology. Methodology: Twenty-four patients who underwent renal biopsy and diagnosed as IgAN before enrolment in the study. Further criteria for inclusion are 24-hour proteinuria excretion over 1.0g/d, serum creatinine (SCr) level below 3mg/dl, grade Ⅲ or Ⅳ tubulointerstitial damages(Lees histologic grading systems). 12 patients (the treatment group) received the combined regime ( TW at dosage of 60mg/d, ACEI And Emodin) and the other 12 patients ( the control group) received treatment with prednisone and benazepril. The responses of the patients were classified as complete remission (CR, defined as proteinuria 0.4 g/24hr, SCr110 mmol/L), partial remission (PR, defined as proteinuria decreased to less than 50% of baseline, SCr kept stable) and No-response (NR, defined as elevated SCr or proteinuria 1.0 g/24hr). A second renal biopsy was performed in 13 patients (9 in the treatment group and 4 in the control group) after 12 months of treatment. Glomerular index (GI), tubular-interstitial index (TI) and vascular index (VI) were quantitatively analyzed by Scion Image Beta 4.0.2 Win software. Results: After six months treatment, there were 5 patients (42%) got to CR, 6 (50%) to PR and 1 (8%) remained refractory to treatment in the treatment group. While there were 2 patients (17%) got to CR, 7 (58%) to PR and 3 (25%) as refractory in the control group. At the end of the 12 months treatment, proteinuria significantly decreased in both groups [(2.04±0.76)g/d vs (0.81±1.09)g/d in the treatment group, P0.05; (1.88±0.67)g/d vs (1.27±1.45)g/d in the control group, P0.05], SCr decreased in the 6 patients with CRF in the treatment group [(140.6±19.0) mmol/L vs (134.1±24.1) mmol/L, P0.05 ]. No significant change of SCr was observed in the 5 patients with CRF in the control group [(126.6±19.6) mmol/L vs(129.5±26.6) mmol/L, P0.05]. Repeated renal biopsy study showed that GI was significantly decreased after the treatment [(0.314±0.054) vs (0.243±0.042), P0.05] in the treatment group, TI and VI were also decreased without statistical difference. No significant changes of GI,TI,VI were observed in the control group. Conclusions: Combined regime of Tripterygium wilfordii plus benazepril and emodin was effective in patients with IgAN by decreasing proteinuria, improving renal function and preventing the progression of renal fibrosis in patients with IgAN. Long-term efficacy of the regime needs further clinical trials.